

Once-daily nepafenac ophthalmic suspension 0.3% to p
inflammation and pain after cataract surgery: Phase 3 s

Journal of Cataract and Refractive Surgery

40, 203-211

DOI: 10.1016/j.jcrs.2013.07.042

Citation Report

#	ARTICLE	IF	CITATIONS
1	Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions. <i>Clinical Ophthalmology</i> , 2014, 8, 1281.	1.8	34
2	Nonbiological pharmacotherapies for the treatment of diabetic macular edema. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2625-2635.	1.8	2
3	Recovery after cataract surgery. <i>Acta Ophthalmologica</i> , 2016, 94, 1-34.	1.1	29
4	Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye. <i>Experimental Eye Research</i> , 2016, 145, 58-67.	2.6	38
5	The comparative efficacy and safety of topical non-steroidal anti-inflammatory drugs for the treatment of anterior chamber inflammation after cataract surgery: a systematic review and network meta-analysis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 639-649.	1.9	51
6	Effect of Green Tea Polyphenol Epigallocatechin-3-gallate on the Aggregation of I \pm A(66-80) Peptide, a Major Fragment of I \pm A-crystallin Involved in Cataract Development. <i>Current Eye Research</i> , 2017, 42, 1368-1377.	1.5	9
7	Management of postoperative inflammation after cataract and complex ocular surgeries: a systematic review and Delphi survey. <i>British Journal of Ophthalmology</i> , 2017, 101, 1451-1460.	3.9	50
8	Topical nepafenac for prevention of post-cataract surgery macular edema in diabetic patients: patient selection and perspectives. <i>Clinical Ophthalmology</i> , 2017, Volume 11, 2183-2190.	1.8	23
9	Neovascular age-related macular degeneration is associated with cataract surgery. <i>Acta Ophthalmologica</i> , 2018, 96, e213-e217.	1.1	16
10	Antiseptic effect of low-concentration povidone-iodine applied with a depot device in the conjunctiva before cataract surgery. <i>Eye</i> , 2018, 32, 1900-1907.	2.1	6
11	0.1% Nepafenac reduces pain and increases patient comfort during cataract surgery. <i>Contact Lens and Anterior Eye</i> , 2018, 41, 448-451.	1.7	4
12	Nepafenac Ophthalmic Suspension 0.3% for the Management of Ocular Pain After Photorefractive Keratectomy. <i>Journal of Refractive Surgery</i> , 2018, 34, 171-176.	2.3	7
13	Evaluation effectiveness of 0.1% nepafenac on injection-related pain in patients undergoing intravitreal Ozurdex injection. <i>Therapeutic Advances in Ophthalmology</i> , 2019, 11, 251584141986185.	1.4	1
14	Pain Control after Intravitreal Injection Using Topical Nepafenac 0.3% or Pressure Patching. <i>Ophthalmology Retina</i> , 2019, 3, 860-866.	2.4	6
15	Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical α -Pulse-Dose. <i>Ophthalmology and Therapy</i> , 2019, 8, 577-587.	2.3	1
16	Analgesic Effect of a Single Drop of Nepafenac 0.3% on Pain Associated with Intravitreal Injections: A Randomized Clinical Trial. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2019, 35, 168-173.	1.4	4
17	Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification. <i>Ophthalmology and Therapy</i> , 2019, 8, 261-270.	2.3	5
18	Advances in ophthalmic preparation: the role of drug nanocrystals and lipid-based nanosystems. <i>Journal of Drug Targeting</i> , 2020, 28, 259-270.	4.4	23

#	ARTICLE	IF	CITATIONS
19	Prodrugs and nanomicelles to overcome ocular barriers for drug penetration. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 885-906.	3.3	42
20	In Vitro and Ex Vivo Evaluation of Nepafenac-Based Cyclodextrin Microparticles for Treatment of Eye Inflammation. Nanomaterials, 2020, 10, 709.	4.1	24
21	Safety and efficacy of nepafenac punctal plug delivery system in controlling postoperative ocular pain and inflammation after cataract surgery. Journal of Cataract and Refractive Surgery, 2021, 47, 158-164.	1.5	9
22	Nepafenac in cataract surgery. Australasian journal of optometry, The, 2022, 105, 263-267.	1.3	0
23	Reply to comment on: Safety and efficacy of a nepafenac punctal plug delivery system in controlling postoperative ocular pain and inflammation after cataract surgery. Journal of Cataract and Refractive Surgery, 2021, 47, 143-144.	1.5	0
24	Recent Developments in Cataract Surgery. , 2020, , 55-97.		9
25	Recent developments in cataract surgery. Annals of Translational Medicine, 2020, 8, 1540-1540.	1.7	23
26	New drug: Nepafenac for cataract surgery. Australian Prescriber, 2017, 40, 246-247.	1.0	0
27	Nepafenac in the Treatment of Ocular Inflammation Following Cataract Surgery (Pseudophakic) Tj ETQq0 0 0 rgBT (Overlock 10 Tf 50 42	0.3	1
28	Comparison of once daily dose of 0.3% nepafenac alone and three times dose of 0.1% nepafenac alone in pain and inflammation control after phacoemulsification. Indian Journal of Ophthalmology, 2022, 70, 807.	1.1	2
29	Recent advances in nanocrystal-based technologies applied for ocular drug delivery. Expert Opinion on Drug Delivery, 2024, 21, 211-227.	5.0	0